Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy

Pil Soo Sung
* ORCID logo ,
Moon Hyung Choi
,
Hyun Yang
,
Soon Kyu Lee
,
Ho Jong Chun
,
Jeong Won Jang
,
Jong Young Choi
,
Seung Kew Yoon
ORCID logo ,
Joon-Il Choi
,
Young Joon Lee
,
Si Hyun Bae
*
Version 1 : Received: 7 August 2020 / Approved: 9 August 2020 / Online: 9 August 2020 (15:34:00 CEST)

How to cite: Sung, P.S.; Choi, M.H.; Yang, H.; Lee, S.K.; Chun, H.J.; Jang, J.W.; Choi, J.Y.; Yoon, S.K.; Choi, J.; Lee, Y.J.; Bae, S.H. Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. Preprints 2020, 2020080218. https://doi.org/10.20944/preprints202008.0218.v1 Sung, P.S.; Choi, M.H.; Yang, H.; Lee, S.K.; Chun, H.J.; Jang, J.W.; Choi, J.Y.; Yoon, S.K.; Choi, J.; Lee, Y.J.; Bae, S.H. Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. Preprints 2020, 2020080218. https://doi.org/10.20944/preprints202008.0218.v1

Abstract

This study aimed to identify the utility of diffusion-weighted magnetic resonance (MR) imaging with an apparent diffusion coefficient (ADC) map as a predictor of the intrahepatic response of hepatocellular carcinoma (HCC) to cisplatin-based hepatic arterial infusion chemotherapy (HAIC). We retrospectively evaluated 113 consecutive patients with HCC who underwent gadoxetic acid-enhanced and diffusion-weighted MR imaging. The appropriate cutoff for the tumor-to-liver ADC ratio was determined to be 0.741. Of the 113 patients, 51 (45%) presented with a tumor-to-liver ADC ratio < 0.741. Evaluation of the intrahepatic treatment response after 2-3 cycles of HAIC in these 51 patients revealed that 20 patients (39%) experienced an objective response to HAIC. On the other hand, only 10 of the 62 patients with a tumor-to-liver ADC ratio ≥ 0.741 (16%) experienced an objective response. Thus, the objective response rate was significantly higher in patients with a tumor-to-liver ADC ratio < 0.741 than in those with a tumor-to-liver ADC ratio ≥ 0.741 (P = 0.006). Multivariate logistic regression analysis using parameters including perfusion alteration, percentage of a non-enhancing portion, and tumor-to-liver ADC ratio revealed that a tumor-to-liver ADC ratio < 0.741 (odds ratio 3.03; P = 0.015) is the sole predictor of an objective response to HAIC. Overall survival rates were significantly higher in patients with objective responses to HAIC than in those without objective responses (P = 0.001 by log-rank test). In conclusion, patients with unresectable HCC with a tumor-to-liver ADC ratio < 0.741 showed a favorable intrahepatic response to HAIC. Therefore, diffusion-weighted MR imaging can play a critical role as a predictor of response to cisplatin-based HAIC in unresectable HCC.

Keywords

hepatocellular carcinoma; diffusion-weighted imaging; magnetic resonance; hepatic arterial infusion chemotherapy

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.